[Demonstration of specific antibodies against diethylstilbestrol during treatment of prostatic cancer].
Antibodies against diethylstilboestrol were detected in prostatic cancer patients treated with diethylstilboestrol (DES). Direct radioimmunoassay (DRIA) was performed in 109 patients divided into three groups: a control group of 33 patients (group I), a group of 38 patients treated by DES and free of cardiovascular complications (group II), and a group of 38 patients treated by DES with cardiovascular complications (group III). Antibody count was significantly higher in group III than in the two other groups (p less than 0.05). These results suggest that DES antibodies may play a role in estrogen-associated cardiovascular toxicity. For this reason, DES should not be used in patients with a positive assay.
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D000906:Antibodies / Q000032:analysis*; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D011863:Radioimmunoassay; D013923:Thromboembolism / Q000139:chemically induced
D000906:Antibodies; D004054:Diethylstilbestrol
Mise en évidence d'anticorps spécifiques anti-diéthylstilboestrol au cours du traitement du cancer prostatique.